Clinical Trials Logo

Clinical Trial Summary

This study evaluates the effect of adaptative Intensity-Modulated Radiation Therapy (IMRT) in the treatment of locally advanced cervical cancer on acute genito-urinary (GU), and gastrointestinal (GI) toxicities. Every patients will be treated according to the adaptative IMRT strategy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02937948
Study type Interventional
Source Center Eugene Marquis
Contact
Status Completed
Phase N/A
Start date April 5, 2017
Completion date April 11, 2022

See also
  Status Clinical Trial Phase
Terminated NCT01234480 - Intended Use Study of the BD SurePath Plus™ Pap
Completed NCT05022511 - Three Birds With One Stone N/A
Recruiting NCT04857528 - Detecting HPV DNA in Anal and Cervical Cancers
Completed NCT01755897 - A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients N/A
Recruiting NCT01667211 - Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer Phase 2
Active, not recruiting NCT01226264 - Diffusion MRI; Predictive Value for Cervical Uterine Cancer Recurrence N/A
Recruiting NCT03961191 - DNA Methylation for Screening Uterine Cervical Lesions: A Case-control Study
Enrolling by invitation NCT01393470 - Evaluation of Long-term HPV Vaccine Efficacy N/A
Terminated NCT00421096 - Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer Phase 2
Terminated NCT01284348 - To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer Phase 2
Recruiting NCT03961178 - A Cohort Study for the Following up of Conization
Terminated NCT02317302 - FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer Phase 1
Not yet recruiting NCT06254846 - Evaluation of First-void Urine as an Alternative to Cervical Sampling for Human Papillomavirus (HPV) Testing in Cervical Cancer Screening (Single-center Study). N/A
Not yet recruiting NCT05824494 - Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors Phase 2
Completed NCT00184093 - Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma Phase 1/Phase 2
Recruiting NCT03960879 - DNA Methylation for Screening Uterine Cervical Lesions
Recruiting NCT04886700 - Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer Phase 2
Completed NCT02095119 - A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer Phase 1/Phase 2
Enrolling by invitation NCT05231993 - Clinical Triage and Treatment of Atypical Glandular Cells (AGC) Detected in Screening N/A
Recruiting NCT02036164 - Adjuvant Chemotherapy for Locally Advanced Cervical Cancer Phase 3